// App-Quantinova.ai

TPS5097 : A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).

Researchers

Presenter

  • Joaquin Mateo

Principal Investigators

  • Daniel Nava Rodrigues

  • Raquel Perez Lopez

  • Nina Tunariu

  • Johann Sebastian De Bono

  • Francois Marc Lokiec

  • Alexander Zukiwski

  • Stefan Proniuk

  • Alice Susannah Bexon

  • Andre Paquin

  • Joseph Bisaha

  • Gerhardt Attard

  • Penelope Flohr

  • Ruth Riisnaes

Medical Centers

  • Centre Rene Huguenin, St Cloud, France

  • Biotrial Rennes, Rennes, FranceBexon Clinical Consulting LLC, Montclair, NJArno Therapeutics, Flemington, NJ

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • France

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Progesterone receptor

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • onapristone

Outcome

  • Unknown

Study Design

  • randomized

  • adaptive

Phase

  • I/II

Study Id's

  • NCT02049190

Sponsors

  • Arno Therapeutics

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved